Transgene secures TG4010 Phase III with rights issue
This article was originally published in Scrip
Transgene has launched a rights issue at €10 per share in the hopes of raising €45m to secure the start of further clinical development of its lead products. The French biopharmaceutical company said this would give it enough cash for the next 12 months whether or not Novartis comes on board for Phase III development of its lead non-small cell lung cancer product TG4010. Transgene's share price dropped by 5% on the news.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.